MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy Meeting Abstract
| Authors: | Spigel, D. R.; Peters, S.; Ahn, M. J.; Tsuboi, M.; Chaft, J.; Harpole, D.; Barlesi, F.; Abbosh, C.; Mann, H.; May, R.; Dennis, P. A.; Swanton, C. |
| Abstract Title: | MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy |
| Meeting Title: | European Lung Cancer Virtual Congress (ELCC 2021 Virtual) |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 16 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2021 Mar 25-27 |
| Meeting Location: | Virtual Conference |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-04-01 |
| Start Page: | S745 |
| End Page: | S746 |
| Language: | English |
| ACCESSION: | WOS:000634855900094 |
| PROVIDER: | wos |
| DOI: | 10.1016/S1556-0864(21)01935-3 |
| Notes: | Meeting Abstract: 93TiP -- Source: Wos |
